-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
As the earliest investor, Qiming Venture Capital led Beihai Kangcheng's Series A financing in 2014 and continued to support it in the Series B financing
Beihai Kangcheng is a leading global biopharmaceutical company based in China and focusing on rare diseases.
At present, Beihai Kangcheng has built a comprehensive pipeline consisting of 13 drug assets, including 3 marketed products, 4 drug candidates in the clinical stage, 1 in the IND preparation stage, 2 in the preclinical stage, and 3 in the preclinical stage.
Dr.
Chen Kan, Executive Director of Qiming Ventures, said: “The team led by Dr.
About Qiming Venture Capital
Qiming Venture Capital was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and San Francisco Bay Area
At present, Qiming Venture Capital manages ten US dollar funds and six RMB funds, with a total of 6.
Up to now, Qiming Ventures has invested in more than 430 fast-growing innovative companies, of which more than 170 are traded on the New York Stock Exchange, Nasdaq, Hong Kong Stock Exchange, Taiwan OTC, Shanghai Stock Exchange and Shenzhen Stock Exchange.
Among Qiming Venture Capital's investment companies, many have grown into the most influential companies in their respective fields, including Xiaomi Group (01810.
